The next generation of PPAR drugs: Do we have the tools to find them?

Agonists of PPARα and PPARγ are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARβ/δ are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPA...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta 2007-08, Vol.1771 (8), p.1082-1093
Main Authors: Shearer, Barry G., Billin, Andrew N.
Format: Article
Language:English
Subjects:
Diabetes Mellitus, Type 2 - drug therapy
Drug Design
Drug discovery
Dyslipidemias - drug therapy
Humans
Hypoglycemic Agents - therapeutic use
Hypolipidemic Agents - therapeutic use
Peroxisome Proliferator-Activated Receptors - agonists
PPAR
PPAR alpha - agonists
PPAR gamma - agonists
Safety
TZD
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Agonists of PPARα and PPARγ are currently approved for use in treating, respectively, dyslipidemia and type 2 diabetes. Agonists of PPARβ/δ are currently in development by several pharmaceutical companies. Despite their therapeutic importance, there are dose limiting side effects associated with PPAR drug treatments, thus a new generation of safer PPAR drugs are being actively sought after. In this review we will discuss the side effects associated the PPARs, how the current drugs in clinical development were discovered and new concepts in how to screen for PPAR drugs.
ISSN:1388-1981
0006-3002
1879-2618
DOI:10.1016/j.bbalip.2007.05.005